OptimizeRx’s (OPRX) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities restated their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX) in a report issued on Tuesday, Benzinga reports. JMP Securities currently has a $15.00 price target on the stock.

Several other research analysts have also weighed in on the stock. Stifel Nicolaus reiterated a buy rating and set a $13.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. Royal Bank of Canada reiterated an outperform rating and set a $17.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. Finally, Barclays initiated coverage on shares of OptimizeRx in a report on Wednesday, January 3rd. They set an equal weight rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, OptimizeRx currently has an average rating of Moderate Buy and a consensus target price of $15.86.

OptimizeRx Price Performance

OptimizeRx stock opened at $9.96 on Tuesday. OptimizeRx has a 12-month low of $6.92 and a 12-month high of $16.65. The stock has a market capitalization of $180.77 million, a P/E ratio of -12.45 and a beta of 0.98. The firm’s 50-day moving average is $13.59 and its two-hundred day moving average is $11.98.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of OPRX. JPMorgan Chase & Co. lifted its position in OptimizeRx by 17.0% during the first quarter. JPMorgan Chase & Co. now owns 13,235 shares of the company’s stock valued at $499,000 after buying an additional 1,920 shares in the last quarter. Raymond James & Associates lifted its position in shares of OptimizeRx by 21.1% during the first quarter. Raymond James & Associates now owns 12,116 shares of the company’s stock worth $457,000 after purchasing an additional 2,111 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of OptimizeRx by 8.3% during the first quarter. Bank of New York Mellon Corp now owns 178,630 shares of the company’s stock worth $6,735,000 after purchasing an additional 13,725 shares in the last quarter. MetLife Investment Management LLC lifted its position in shares of OptimizeRx by 58.3% during the first quarter. MetLife Investment Management LLC now owns 9,158 shares of the company’s stock worth $345,000 after purchasing an additional 3,371 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of OptimizeRx by 12.8% during the first quarter. Rhumbline Advisers now owns 42,886 shares of the company’s stock worth $1,617,000 after purchasing an additional 4,878 shares in the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.